Turnstone Biologics
Turnstone Biologics is pioneering next-generation tumor infiltrating lymphocyte (TIL) therapies called Selected TILs, leveraging viral immunotherapy to enhance their activity against solid tumors.
Turnstone Biologics Services
Turnstone Biologics is involved in developing advanced cell therapies for cancer treatment. The company specializes in Selected TIL (Tumor Infiltrating Lymphocyte) therapies, leveraging their proprietary selection process to identify and expand the most potent and tumor-reactive T cells. Additionally, the company employs viral immunotherapy to enhance the efficacy of their TIL treatments. Their services include clinical trials, strategic alliances, and cooperative research agreements.
Turnstone Biologics Founders
Turnstone Biologics was founded to pioneer innovative cancer treatments. While the specific founders are not mentioned, the company's leadership is focused on leveraging expertise in viral immunotherapy and T-cell selection. The headquarters are in La Jolla, California, with additional locations in New York and Ottawa, Ontario.
Turnstone Biologics Products
Turnstone Biologics' primary products include their next-generation Selected TIL therapies and their lead clinical stage viral immunotherapy program, RIVAL-01. RIVAL-01 is designed to drive oncolytic and immune-mediated tumor cell destruction and is being developed in partnership with Takeda. Additionally, the company has an ongoing Phase 1 trial for their lead TIL therapy candidate, TIDAL-01. Their proprietary vaccinia virus platform enhances immune activation, viral activity, and local therapeutic expression.
Turnstone Biologics Strategic Partnerships
Turnstone Biologics maintains several strategic partnerships to advance their therapies. They have a Cooperative Research and Development Agreement with the National Cancer Institute (NCI) to study the combination of TIL and viral immunotherapy. They also have a strategic alliance with Moffitt Cancer Center focusing on their tumor-reactive Selected TIL pipeline. Additionally, they have announced a TIL therapy research collaboration with CRCHUM to explore novel tumor-reactive T-cell selection strategies.
Turnstone Biologics Financial Background
Turnstone Biologics has successfully secured $80 million in Series D financing to support the development of their oncolytic virus and TIL therapy candidates. The company went public in July 2023, trading on the Nasdaq Global Select Market under the symbol 'TSBX'. This financial backing facilitates the continued development and scaling of their innovative cancer therapies.